ViaCyte Competitors and Similar CompaniesClear all
ViaCyte's competitors and similar companies include Profil, KalVista Pharmaceuticals, Kerecis and Fractyl Health.
 ViaCyte ViaCyte is a regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. |  Profil Profil Institut für Stoffwechselforschung is a clinical research organisation for studies related to diabetes and obesity. |  KalVista Pharmaceuticals KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME). |  Kerecis Kerecis develops, manufactures and markets patented Omega3 rich fish skin, in skin and tissue repair. |  Fractyl Health Fractyl Health (formerly known as Fractyl Laboratories) is a metabolic therapeutics company that develops therapies for treating type 2 diabetes (T2D) and obesity. | |
Founding Date | Founding Date 1999 | Founding Date 1999 | Founding Date 2011 | Founding Date 2011 | Founding Date 2010 |
Type | Type Private | Type Private | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations Neuss, DE HQ Mainz, DE | Locations Porton Down, GB HQ Cambridge, US | Locations Arlington, US HQ Ísafjörður, IS Reykjavík, IS Reykjavík, IS | Locations Burlington, US HQ |
Employees | Employees 176% decrease | Employees 200 | Employees 150 | Employees 512 | Employees 88 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 523.4 m | Valuation ($) N/A | Valuation ($) 163 m |
Financial | |||||
Net income | Net income N/A | Net income N/A | Net income ($109.5m) (FY, 2025) | Net income N/A | Net income ($141m) (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round $ 45m (almost 5 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 16m (almost 7 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 246.9m | Total funding raised N/A | Total funding raised $ 46.2m | Total funding raised $ 27.6m | Total funding raised $ 190.1m |
For sources of this data, please see the company profile
View Company Profiles
Profil
HQ
Neuss, DE
Employees
200
Profil Institut für Stoffwechselforschung is a clinical research organisation for studies related to diabetes and obesity.
View companyKalVista Pharmaceuticals
HQ
Porton Down, GB
Employees
150
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
View companyKerecis
HQ
Arlington, US
Employees
512
Kerecis develops, manufactures and markets patented Omega3 rich fish skin, in skin and tissue repair.
View companyFractyl Health
HQ
Burlington, US
Employees
88
Fractyl Health (formerly known as Fractyl Laboratories) is a metabolic therapeutics company that develops therapies for treating type 2 diabetes (T2D) and obesity.
View company